Literature DB >> 24285019

Aprepitant does not alter prednisolone pharmacokinetics in patients treated with R-CHOP.

K Maie1, Y Okoshi, N Takaiwa, N Kurita, Y Hasegawa, M Homma, K Ishii, Y Kohda, S Chiba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24285019     DOI： 10.1093/annonc/mdt477

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Aprepitant and fosaprepitant drug interactions: a systematic review.

Authors:  Priya Patel; J Steven Leeder; Micheline Piquette-Miller; L Lee Dupuis
Journal:  Br J Clin Pharmacol       Date:  2017-06-10       Impact factor: 4.335

2.  Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials.

Authors:  Lucas Miyake Okumura; Fernanda D'Athayde Rodrigues; Maria Angelica Pires Ferreira; Leila Beltrami Moreira
Journal:  Br J Clin Pharmacol       Date:  2017-01-12       Impact factor: 4.335

Review 3.  Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.

Authors:  Matti Aapro; Alexandra Carides; Bernardo L Rapoport; Hans-Joachim Schmoll; Li Zhang; David Warr
Journal:  Oncologist       Date:  2015-03-20

4.  A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin's lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists.

Authors:  Tsutomu Takahashi; Satoshi Kumanomidou; Saki Takami; Takahiro Okada; Koji Adachi; Yumi Jo; Fumiyoshi Ikejiri; Chie Onishi; Koshi Kawakami; Takaaki Miyake; Masaya Inoue; Ichiro Moriyama; Ritsuro Suzuki; Junji Suzumiya
Journal:  Int J Hematol       Date:  2016-06-16       Impact factor: 2.490
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.